CStone's Pratinib thyroid cancer indication was accepted and included in priority review

Recently, the cornerstone of medicine (2616, HK) announced that selective inhibitors of RET Phuket, Hua ^® (imatinib Pula capsules) Indications application has been extended Chinese State Drug Administration (NMPA) acceptance and inclusion in the priority review The extended indications include advanced or metastatic transfection rearrangement (RET) gene mutation medullary thyroid carcinoma (MTC) that requires systemic treatment, and those that require systemic treatment and are refractory to radioactive iodine (if radioactive iodine is suitable) Advanced or metastatic RET fusion-positive thyroid cancer.

Thyroid cancer is the most common endocrine malignant tumor, and its incidence has increased significantly in recent years.

RET fusion and activating mutations are key disease drivers in many cancer types, including NSCLC and many types of thyroid cancer.

The Phuket Hua ^® Extended indications of acceptance is a global clinical research phase I / II ARROW-based study designed to evaluate the integration of Pula imatinib in RET-positive non-small cell lung cancer, thyroid cancer as well as other carry RET mutation Safety, tolerability and effectiveness in patients with advanced solid tumors.